Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $15.00

Aveanna Healthcare (NASDAQ:AVAH) had its price objective upped by Truist Financial from $11.00 to $15.00 in a report released on Monday,Benzinga reports. Truist Financial currently has a hold rating on the stock.

Several other equities research analysts have also issued reports on the stock. Raymond James Financial lifted their price target on shares of Aveanna Healthcare from $13.00 to $15.00 and gave the company a “strong-buy” rating in a report on Friday, August 14th. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. Barclays raised their target price on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research report on Thursday, July 9th. BMO Capital Markets boosted their target price on shares of Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Finally, Wall Street Zen downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.89.

Aveanna Healthcare Stock Performance

Aveanna Healthcare stock opened at $13.62 on Monday. Aveanna Healthcare has a 12-month low of $5.93 and a 12-month high of $13.98. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 4.47. The business’s 50-day moving average price is $9.95 and its two-hundred day moving average price is $8.03. The stock has a market cap of $2.97 billion, a PE ratio of 11.07, a P/E/G ratio of 0.85 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last issued its earnings results on Thursday, August 13th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.17 by $0.05. The firm had revenue of $670.48 million during the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. As a group, analysts expect that Aveanna Healthcare will post 0.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Robert M. Williams, Jr. sold 14,500,002 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $166,750,023.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Paul R. Vigano sold 14,500,002 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $166,750,023.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 79,746,745 shares of company stock valued at $773,117,091 in the last three months. Insiders own 5.30% of the company’s stock.

Institutional Trading of Aveanna Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVAH. AQR Capital Management LLC increased its position in Aveanna Healthcare by 21.2% during the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after purchasing an additional 4,602 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Aveanna Healthcare by 8.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after purchasing an additional 25,974 shares during the period. Jane Street Group LLC lifted its position in shares of Aveanna Healthcare by 522.0% in the 1st quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock worth $407,000 after purchasing an additional 63,010 shares during the period. Creative Planning boosted its stake in shares of Aveanna Healthcare by 15.1% in the 2nd quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after purchasing an additional 6,171 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Aveanna Healthcare by 65.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after purchasing an additional 62,348 shares during the last quarter. Institutional investors and hedge funds own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.